



Insulin Manufacturing Facility – Syria

The Opportunity

Diabetes affects over 1.1 million people in Syria, yet domestic insulin production is nonexistent. This project proposes the establishment of a GMP-certified insulin manufacturing facility capable of producing multiple insulin types—including regular, NPH, and analog formulations—to address local demand and export to neighboring markets.

Market Demand

- 1.1M+ diabetic patients in Syria, with increasing incidence
- Reliance on costly and irregular imports
- High demand from Iraq, Jordan, and North Africa
- Global insulin market expected to exceed \$80B by 2030

Investment Snapshot

- Capital Requirement: \$18–25 million
- Facility Capacity: 10M vials per year
- Break-even: Year 4
- WHO prequalification targeted in Year 3 for exports

Competitive Advantage

- Vertical integration potential (vials, syringes, packaging)
- Significant cost advantage over imported insulin
- Technology transfer from established insulin makers
- Positioned for public tenders and humanitarian procurement

Strategic Impact

- Reduces mortality and complications among diabetic patients
- Builds pharmaceutical sovereignty
- Creates 500+ skilled and semi-skilled jobs